Epalrestat Improves Diabetic Wound Healing via Increased Expression of Nerve Growth Factor

Abstract

Aims/Introduction:

Aldose reductase inhibitors (ARIs) are a useful therapy for diabetic neuropathy. Nerve damage is associated with delayed wound healing of skin ulcers in diabetic patients. Therefore, we hypothesized that ARI supplementation would improve diabetic wound healing.

Materials and methods:

Control and streptozotocin-induced diabetic mice were fed either control diet or diet containing the ARI Epalrestat (40 mg/kg). After 12 weeks, we created skin wounds on the backs of the mice. Wound healing was determined by measuring the reduction in wound area.

Results:

The wound gap of the diabetic group was significantly larger 9 days after creating the wounds when compared to the other groups (p<0.01). Interestingly, wound healing in the diabetic mice fed Epalrestat was comparable to the non-diabetic mice. To clarify the mechanism(s) behind this improved wound healing, mRNA expression of growth factors reported to be involved in wound healing were examined. Among the growth factors investigated, only the expression of nerve growth factor (NGF) was ­significantly decreased (54.0%) in the healing lesions of diabetic mice. Similarly, NGF protein expression was decreased in diabetic mice and recovered in Epalrestat treated diabetic mice. Inhibition of NGF via 2 separate inhibitors (K252a and BSO) reduced the ability of Epalrestat to improve wound healing in diabetic mice.

Conclusions:

These findings suggest that Epalrestat is a potential therapy for improving diabetic wound healing and the mechanism involves upregulation of NGF.

Key words

aldose reductase inhibitor - wound healing - nerve growth factor

• References

• 1 Chalk C, Benstead TJ, Moore F. Aldose reductase inhibitors for the treatment of diabetic polyneuropathy. Cochrane Database Syst Rev. 2007
• 2 Chudzik W, Kaczorowska B, Przybyla M et al. Diabetic neuropathy. Pol Merkur Lekarski 2007; 22: 66-69
• 3 Baba LM, Kimura K, Suda T, Yagihashi S. Three-year inhibition of aldose reductase on development of symptomatic neuropathy in diabetic patients. Journal of the Peripheral Nervous System 2006; 11: 3
• 4 Hara F, Samuel S, Liu J et al. A homeobox gene related to Drosophila distal-less promotes ovarian tumorigenicity by inducing expression of vascular endothelial growth factor and fibroblast growth factor-2. Am J Pathol 2007; 170: 1594-1606
• 5 Gibran NS, Jang YC, Isik FF et al. Diminished neuropeptide levels contribute to the impaired cutaneous healing response associated with diabetes mellitus. J Surg Res 2002; 108: 122-128
• 6 Barrientos S, Stojadinovic O, Golinko MS et al. Growth factors and cytokines in wound healing. Wound Repair Regen 2008; 16: 585-601
• 7 Gurtner GC, Werner S, Barrandon Y et al. Wound repair and regeneration. Nature 2008; 453: 314-321
• 8 Muangman P, Muffley LA, Anthony JP et al. Nerve growth factor accelerates wound healing in diabetic mice. Wound Repair Regen 2004; 12: 44-52
• 9 Fujimoto J, Limuro Y. Growth factor. Surgery Frontier 2007; 14: 1
• 10 Barker AR, Rosson GD, Dellon AL. Wound Healing in Denervated Tissue. Ann Plast Surg 2006; 57: 4
• 11 Pradhan L, Nabzdyk C, Andersen ND et al. Inflammation and neuropeptides: the connection in diabetic wound healing. Expert Rev Mol Med 2009; 11
• 12 Nishihara R, Sugano N, Takano M et al. The effect of Porphyromonas gingivalis infection on cytokine levels in type 2 diabetic mice. J Periodontal Res 2009; 44: 305-310
• 13 Strissel KJ, Stancheva Z, Miyoshi H et al. Adipocyte death, adipose tissue remodeling, and obesity complications. Diabetes 2007; 56: 2910-2918
• 14 Stefanato CM, Yaar M, Bhawan J et al. Modulations of nerve growth factor and Bcl-2 in ultraviolet-irradiated human epidermis. J Cutan Pathol 2003; 30: 351-357
• 15 Zhou Z, Kawana S, Aoki E et al. Dynamic changes in nerve growth factor and substance P in the murine hair cycle induced by depilation. J Dermatol 2006; 33: 833-841
• 16 Graiani G, Emanueli C, Desortes E et al. Nerve growth factor promotes reparative angiogenesis and inhibits endothelial apoptosis in cutaneous wounds of Type 1 diabetic mice. Diabetologia 2004; 47: 1047-1054
• 17 Liu Y, Cai S, Shu XZ et al. Release of basic fibroblast growth factor from a crosslinked glycosaminoglycan hydrogel promotes wound healing. Wound Repair Regen 2007; 15: 245-251
• 18 Yoshida S, Matsumoto K, Tomioka D et al. Recombinant hepatocyte growth factor accelerates cutaneous wound healing in a diabetic mouse model. Growth Factors 2004; 22: 111-119
• 19 Sofroniew MV, Howe CL, Mobley WC. Nerve growth factor signaling, neuroprotection, and neural repair. Annu Rev Neurosci 2001; 24: 1217-1281
• 20 Ohi T, Saita K, Furukawa S et al. Therapeutic effects of aldose reductase inhibitor on experimental diabetic neuropathy through synthesis/secretion of nerve growth factor. Exp Neurol 1998; 151: 215-220
• 21 Tomlinson DR, Fernyhough P, Diemel LT. Role of neurotrophins in diabetic neuropathy and treatment with nerve growth factors. Diabetes 1997; 46: 43-49
• 22 Matsuda H, Koyama H, Sato H et al. Role of nerve growth factor in cutaneous wound healing: accelerating effects in normal and healing-impaired diabetic mice. J Exp Med 1998; 187: 297-306
• 23 Apfel SC, Kessler JA, Adornato BT et al. Recombinant human nerve growth factor in the treatment of diabetic polyneuropathy. NGF Study Group. Neurology 1998; 51: 695-702
• 24 McArthur JC, Yiannoutsos C, Simpson DM et al. A phase II trial of nerve growth factor for sensory neuropathy associated with HIV infection. AIDS Clinical Trials Group Team 291. Neurology 2000; 54: 1080-1088
• 25 Apfel SC, Schwartz S, Adornato BT et al. Efficacy and safety of recombinant human nerve growth factor in patients with diabetic polyneuropathy: A randomized controlled trial. rhNGF Clinical Investigator Group. JAMA: the journal of the American Medical Association 2000; 284: 2215-2221
• 26 Generini S, Tuveri MA, Matucci Cerinic M et al. Topical application of nerve growth factor in human diabetic foot ulcers. A study of three cases. Experimental and clinical endocrinology & diabetes: official journal. German Society of Endocrinology [and] German Diabetes Association 2004; 112: 542-544
• 27 Tiaka EK, Papanas N, Manolakis AC et al. The role of hyperbaric oxygen in the treatment of diabetic foot ulcers. Angiology 2012; 63: 302-314
• 28 Riaz S, Malcangio M, Miller M et al. A vitamin D(3) derivative (CB1093) induces nerve growth factor and prevents neurotrophic deficits in streptozotocin-diabetic rats. Diabetologia 1999; 42: 1308-1313
• 29 Calcutt NA, Freshwater JD, Hauptmann N et al. Protection of sensory function in diabetic rats by Neotrofin. European journal of pharmacology 2006; 534: 187-193
• 30 Suzuki T, Sekido H, Kato N et al. Neurotrophin-3-induced production of nerve growth factor is suppressed in Schwann cells exposed to high glucose: involvement of the polyol pathway. J Neurochem 2004; 91: 1430-1438